Abstracts Archive - Page 73 of 2607 - ACR Meeting Abstracts

Abstract Number: 0163 • ACR Convergence 2025
Trends in hospitalization and outcomes among patients admitted with Adult-onset Still’s disease in the United States: INSIGHTS FROM THE NATIONAL INPATIENT SAMPLE (2016-2022)
Mohammed Akram¹, Muhammad Sohaib Asghar², Woo Joo Lee², Basmah Fayaz Yousuf³, Carmen Tormo Carillo⁴ and Savier Aleman Rama⁴, ¹HCA Aventura, Aventura, FL, ²AdventHealth Sebring, Sebring, FL, ³SUNY Downstate Health Sciences University, New York, NY, ⁴HCA Florida Aventura Hospital, Aventura, FL
Background/Purpose: Adult-onset Still's Disease is a rare systemic autoinflammatory disorder characterized by spiking fever, arthralgia/arthritis, skin rash, and elevated inflammatory markers (ferritin). Estimated incidence ranges…
Abstract Number: 0086 • ACR Convergence 2025
Androgen Upregulates Interferon Signaling in Osteoclast Differentiation During Inflammatory State
Kiana Chen¹, Chia-Lung Wu², Gulzada Kulzhanova² and Homaira Rahimi³, ¹University of Rochester School of Medicine and Dentistry, Bronx, NY, ²University of Rochester Medical Center, Rochester, ³University of Rochester, Rochester, NY
Background/Purpose: Rheumatoid arthritis (RA) is characterized by chronic inflammatory erosions and female predominant disease. Androgen, the dominant sex hormone in males, is protective against bone…
Abstract Number: 0061 • ACR Convergence 2025
IL-22 Contributes to Autoantibody-induced Arthritis Via Modulation of Inflammatory Cytokine and Chemokine Expression in the Inflamed Synovium of a Murine Model
Shinjiro Kaieda¹, Suzuna Sugi¹, Takuma Koga², Takashi Kinoshita¹ and Tomoaki Hoshino¹, ¹Kurume university School of Medicine, Kurume, Japan, ²Kurume Universty School of Medicine, Kurume, Japan
Background/Purpose: IL-22 is a key cytokine involved in modulating tissue responses during inflammation and is markedly upregulated in inflammatory diseases, such as psoriasis, inflammatory bowel…
Abstract Number: 0204 • ACR Convergence 2025
Immunogenicity and safety summary for the chikungunya virus-like particle vaccine development programme
Lauren Tindale¹, Jason Richardson¹, Deborah Anderson¹, Jason Mendy², Sufia Muhammad², Tobi Loreth¹, Victoria Jenkins³, Krystal Valenzuela⁴, Benedetto Simone⁵, Patrick Ajiboye² and Lisa Bedell⁴, ¹Bavarian Nordic Canada Inc., Toronto, Canada, ²Bavarian Nordic, Inc., San Diego, ³Bavarian Nordic Belgium, Brussels, Belgium, ⁴Bavarian Nordic, Inc., Durham, ⁵Bavarian Nordic Berna GmbH, Thoerishaus, Switzerland
Background/Purpose: Chikungunya virus (CHIKV) is a threat to public health and a risk for travellers to endemic countries. Typical acute symptoms include fever, arthralgia, myalgia,…
Abstract Number: 0184 • ACR Convergence 2025
Neurocognitive Complications of Lupus: A Multidisciplinary Program Model for Advanced Diagnostics, Management, and Clinical Research
Douglas Wilcox¹, Matthew Baum², Sophie Lebiedz², John Sullivan², Margaret Naclerio², Jonathan Zurawski², Bonnie Glanz², Rohit Bakshi², Tanuja Chitnis², Shamik Bhattacharyya³ and Karen H. Costenbader⁴, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, ³Brigham and Women's Hospital, Malden, MA, ⁴Harvard Medical School and Brigham and Women's Hospital, Boston, MA
Background/Purpose: Neurological symptoms in lupus are common and occur in the majority of patients with SLE. Although neuropsychiatric lupus (NPSLE) can involve the entire nervous…
Abstract Number: 0109 • ACR Convergence 2025
Application of Psoriatic Arthritis Mouse Models in Preclinical Pharmacodynamic Evaluation
Juan Liang¹ and Yinlian Zhang², ¹Gempharmatech, Nanjing, Jiangsu, China, ²GemPharmatech, Nanjing, China (People's Republic)
Background/Purpose: Psoriatic arthritis (PsA), a complex inflammatory disorder that affects up to 30% of psoriasis patients. It is marked by clinical heterogeneity and a lack…
Abstract Number: 0193 • ACR Convergence 2025
Evaluation of electronic health record and efficiency tool utilization by pediatric subspecialists
Samantha Coss¹, Alison Brittain², Jennifer Lee³, Julie Young¹, Ivana Stojkic¹, John Mahan⁴ and Alysha Taxter⁵, ¹Nationwide Children's Hospital, Columbus, OH, ²Nationwide Children's Hospital, Canal Winchester, OH, ³Department of Gastroenterology, Nationwide Children's Hospital, Columbus, OH, ⁴Department of Nephrology, Nationwide Children's Hospital, Columbus, OH, ⁵Nationwide Children's, Columbus, OH
Background/Purpose: Excessive interaction with the electronic health record (EHR) is frequently cited as a common source of physician burnout. The administrative burden and extended documentation…
Abstract Number: 2280 • ACR Convergence 2025
Changes of B Cell Subsets During Treatment with Abatacept in Patients with Rheumatoid Arthritis
Athanasios Mavropoulos¹, Christos Liaskos², Ioannis Alexiou³, Christina Katsiari⁴, Dimitrios Bogdanos⁵ and Lazaros Sakkas⁶, ¹University of Thessaly, Volos, Greece, ²University of Thessaly, Faculty of Medicine, Larisa, Greece, ³University General Hospital of larissa, Larissa, Greece, ⁴University General Hospital of Larisa, University of Thessaly Faculty of Medicine, Larisa, Greece, ⁵Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece, ⁶Department of Rheumatology, University of Thessaly, Larissa, Greece
Background/Purpose: Abatacept, an efficacious therapy for rheumatoid arthritis (RA), inhibits the interaction between CD28 on T cells and CD80/CD86 on antigen-presenting cells (APCs). The aim…
Abstract Number: 0176 • ACR Convergence 2025
Development and Validation of an Accurate Patient Reported Outcome Measure-based Disease Activity Score to Enable Remote Monitoring in RA
Agnes Looijen¹, Paco Welsing², Sytske Anne Bergstra³, Annette van der Helm-van Mil³ and Pascal de Jong⁴, ¹Erasmus MC, Rotterdam, Netherlands, ²Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands, Utrecht, Netherlands, ³LUMC, Leiden, Netherlands, ⁴Erasmus University Medical Center, Rotterdam, the Netherlands, Rotterdam, Netherlands
Background/Purpose: For RA patients, regular monitoring of disease activity is essential, but in-person assessments may not always be feasible due to the increasing pressure on…
Abstract Number: 0114 • ACR Convergence 2025
A rare variant in the Extl3 gene is associated with altered Wnt signaling pathway in a novel mouse model of axial spondyloarthritis
Stéphane HILLIQUIN¹, Karim IBRAHIM², Olivier Fogel³, Marcio DO CRUZEIRO⁴, Patricia Albanese⁵, Xavier HOUARD⁶, Claire BARDET² and Corinne MICELI-RICHARD⁷, ¹Département de Rhumatologie, Hôpital Cochin, Assistance publique des Hôpitaux de Paris, Université Paris-Cité, Paris, France, PARIS, France, ²Université Paris Cité, Institut des maladies musculo-squelettiques, Laboratory Orofacial Pathologies, UMR-S ¹³³³ Santé Orale and FHU-DDS-Net, Dental School, and Plateforme d’Imagerie du Vivant (PIV), Montrouge, France, Montrouge, France, ³AP-HP, Paris, France, ⁴Plateformes PDA et MouseT'IC, Institut Cochin, Université Paris Cité, Paris, France, Paris, France, ⁵Laboratoire Gly-CREET, Université Paris-Est Créteil Val de Marne (UPEC) Faculté des sciences et technologies, Créteil, France, ⁶Centre de Recherche Saint-Antoine, UMR_S⁹³⁸ INSERM /Sorbonne Université, Paris, France, PARIS, France, ⁷Rheumatology Department, Hôpital Cochin, APHP, PARIS, France
Background/Purpose: The ossification processes observed in ankylosing spondylitis (AS) remain incompletely understood. Substantial evidence from both human and animal studies implicates the Wnt signaling pathway…
Abstract Number: 0024 • ACR Convergence 2025
Biobank-scale genetic mapping identifies the shared genetic landscape of rheumatic and cardiovascular disease
Daniel Panyard¹, Daniel Li², Pik Fang Kho², Rodrigo Guarischi-Sousa³, Jiayan Zhou², Austin Hilliard⁴, Christie Bartels⁵, Philip Tsao² and Themistocles Assimes², ¹Stanford University, Sunnyvale, CA, ²Stanford University, Palo Alto, CA, ³Palo Alto Veterans Institute for Research, Palo Alto, CA, ⁴VA Palo Alto Health Care, Palo Alto, CA, ⁵University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Patients with rheumatic conditions are at increased risk for cardiovascular (CV) problems, striking on average a decade before peers and conferring substantial morbidity and…
Abstract Number: 0095 • ACR Convergence 2025
Effect of JAK Inhibitors on Osteoblast Differentiation
Toshihiro Tanioka¹ and Takeo Isozaki², ¹Graduate School of Pharmacy, Showa Medical University, Shinagawa-ku,Tokyo, Tokyo, Japan, ²Graduate School of Pharmacy, Showa Medical University, Tokyo, Tokyo, Japan
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation and joint destruction. Among the therapeutic strategies available, Janus kinase (JAK) inhibitors have…
Abstract Number: 0194 • ACR Convergence 2025
Evaluation of a Home-based Therapeutics Service: Feasibility, Patient and Caregiver Experience, and Cost
Xiaohui Xin, Andrea Low, Sow Ling Yee, Miao Miao Liu, Christina Tan, Daphne Ng and Siaw Ing Yeo, Singapore General Hospital, Singapore, Singapore
Background/Purpose: The home-based therapeutics service (HTS) by a community nurse is part of an ongoing larger initiative—Community Therapeutics Programme (CTP)—spearheaded by the Rheumatology and Immunology…
Abstract Number: 0044 • ACR Convergence 2025
DNA Methylation Signatures in Systemic Lupus Erythematosus and Rheumatoid Arthritis Highlight Divergent Immune Pathways
Rufei Lu¹, Tayte Stephens², Carla Guthridge¹, Miles Smith¹, Joseph Kheir¹, Cristina Arriens¹, Joan Merrill³, Marci Beel⁴, Susan Macwana¹, Wade DeJager⁵, Nicholas Domingez¹, Teresa Aberle¹, Joel Guthridge¹ and Judith James¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Oklahoma Health Science Center, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City ⁷³¹⁰⁴, OK, ⁴Oklahoma Medical Research Foun, Oklahoma City, OK, ⁵Oklahoma Medical Research Foundation, Oklahoma City
Background/Purpose: Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are autoimmune diseases with distinct clinical and immunopathological features. Epigenetic modifications, particularly DNA methylation, contribute to…
Abstract Number: 0200 • ACR Convergence 2025
Severe infections and malignancies in patients with cranial and extracranial giant cell arteritis treated with tocilizumab. National multicenter study of 471 patients of clinical practice
Adrian Martin-Gutierrez¹, Javier Loricera², Vicente Aldasoro Cáceres³, Olga Maiz⁴, Eugenio de Miguel⁵, Eva Galíndez Agirregoikoa⁶, Ivan Ferraz Amaro⁷, Santos Castañeda⁸ and Ricardo Blanco⁹, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Renedo de Piélagos, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³Hospital Universitario de Navarra, Pamplona, Spain, ⁴Hospital Universitario de Donosti, Donostia, Spain, ⁵Hospital Universitario La Paz, Madrid, Spain, ⁶BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ⁷Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁸Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ⁹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Infections and malignancies are two of the most feared side effects of biologic therapies. Giant cell arteritis (GCA) is a vasculitis which affects older…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].